Joel M. Kremer
Experienced in Fibromyalgia

Dr. Joel M. Kremer

Rheumatology
4 Tower Pl, 8th Floor, 
Albany, NY 
47 Years of Experience
Experienced in Fibromyalgia
4 Tower Pl, 8th Floor, 
Albany, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joel Kremer is a Rheumatologist in Albany, New York. Dr. Kremer has been practicing medicine for over 47 years and is rated as an Experienced provider by MediFind in the treatment of Fibromyalgia. His top areas of expertise are Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, Psoriasis, and Laminectomy.

His clinical research consists of co-authoring 221 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Fibromyalgia.

Specialties
Rheumatology
Licenses
Specialist in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4 Tower Pl, 8th Floor, Albany, NY 12203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
Enrollment Status: Completed
Publish Date: October 26, 2022
Intervention Type: Drug
Study Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab
Study Phase: Phase 4
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug, Biological
Study Drug: Zostavax Herpes Zoster Vaccine
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

220 Total Publications

Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients.
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients.
Journal: Arthritis care & research
Published: May 14, 2025
Similar Doctors
Distinguished in Fibromyalgia
Dr. Dorota L. Hausner-Sypek
Rheumatology
Distinguished in Fibromyalgia
Dr. Dorota L. Hausner-Sypek
Rheumatology

The Center For Rheumatology Llp

4 Tower Pl, Fl 8, 
Albany, NY 
 (0.1 miles away)
518-489-4471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dorota Hausner-Sypek is a Rheumatologist in Albany, New York. Dr. Hausner-Sypek is rated as a Distinguished provider by MediFind in the treatment of Fibromyalgia. Her top areas of expertise are Rheumatoid Lung Disease, Rheumatoid Pneumoconiosis, Rheumatoid Vasculitis, and Ankylosing Spondylitis.

Advanced in Fibromyalgia
Dr. Edmund H. Hornstein
Rheumatology
Advanced in Fibromyalgia
Dr. Edmund H. Hornstein
Rheumatology

Berkshire Medical Center Inc

725 N St, 
Pittsfield, MA 
 (34.0 miles away)
413-447-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edmund Hornstein is a Rheumatologist in Pittsfield, Massachusetts. Dr. Hornstein is rated as a Distinguished provider by MediFind in the treatment of Fibromyalgia. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Rheumatoid Arthritis (RA), and Undifferentiated Connective Tissue Disease (UCTD). Dr. Hornstein is currently accepting new patients.

Advanced in Fibromyalgia
Dr. James Yovanoff
Rheumatology
Advanced in Fibromyalgia
Dr. James Yovanoff
Rheumatology
161 Carey Rd, 
Queensbury, NY 
 (42.8 miles away)
518-824-8610
Languages Spoken:
English

James Yovanoff is a Rheumatologist in Queensbury, New York. Dr. Yovanoff is rated as an Advanced provider by MediFind in the treatment of Fibromyalgia. His top areas of expertise are Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, Rheumatoid Arthritis (RA), and Fibromyalgia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kremer's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile